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Background: Domoic acid (DA) is an excitatory amino acid analogue of kainic acid (KA) that acts via activation of
glutamate receptors to elicit a rapid and potent excitotoxic response, resulting in neuronal cell death. Recently, DA
was shown to elicit reactive oxygen species (ROS) production and induce apoptosis accompanied by activation of
p38 mitogen-activated protein kinase (MAPK) in vitro. We have reported that WDR35, a WD-repeat protein, may
mediate apoptosis in several animal models. In the present study, we administered DA to rats intraperitoneally, then
used liquid chromatography/ion trap tandem mass spectrometry (LC-MS/MS) to identify and quantify DA in the
brains of the rats and performed histological examinations of the hippocampus. We further investigated the
potential involvement of glutamate receptors, ROS, p38 MAPK, and WDR35 in DA-induced toxicity in vivo.
Results: Our results showed that intraperitoneally administered DA was present in the brain and induced
neurodegenerative changes including apoptosis in the CA1 region of the hippocampus. DA also increased the
expression of WDR35 mRNA and protein in a dose- and time-dependent manner in the hippocampus. In experiments
using glutamate receptor antagonists, the AMPA/KA receptor antagonist NBQX significantly attenuated the DA-induced
increase in WDR35 protein expression, but the NMDA receptor antagonist MK-801 did not. In addition, the radical
scavenger edaravone significantly attenuated the DA-induced increase in WDR35 protein expression. Furthermore,
NBQX and edaravone significantly attenuated the DA-induced increase in p38 MAPK phosphorylation.
Conclusion: In summary, our results indicated that DA activated AMPA/KA receptors and induced ROS production and
p38 MAPK phosphorylation, resulting in an increase in the expression of WDR35 in vivo.
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Domoic acid (DA) is an excitatory amino acid analogue of
kainic acid (KA) that acts through glutamate receptors to
elicit a rapid and potent excitotoxic response, resulting in
prolonged receptor activation, tonic depolarization and
neuronal hyperexcitability, excessive Ca2+ influx, and ul-
timately widespread neuronal loss [1,2]. Several studies* Correspondence: evrv@aichi-med-u.ac.jp
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distribution, and reproduction in any mediumhave reported that the toxicity of DA is mainly mediated by
the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)/KA receptor in immature and mature neu-
rons and glia from rat cerebellum [3,4]. Furthermore,
Giordano et al. [5] reported that an AMPA/KA receptor
antagonist, but not an N-methyl-D-aspartate (NMDA) re-
ceptor antagonist, prevents DA-induced apoptosis in pri-
mary cultures of granule cells from mouse cerebellum.
The induction of neuronal cell death by DA in vitro is
mediated by an increase in the production of reactivetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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number of events and pathways that lead to apoptosis, in-
cluding mitogen-activated protein kinase (MAPK) signal
transduction pathways [9]. In neuronal cells, p38 MAPK is
preferentially activated by environmental stress and inflam-
matory cytokines, and it has been shown to promote neur-
onal cell death in vitro [10]. A recent study demonstrated
that DA-induced cell death in primary neuronal cultures
involves activation of p38 MAPK, and antioxidants pre-
vented p38 MAPK phosphorylation [11]. Collectively, these
lines of evidence suggest that DA induces ROS generation
followed by p38 MAPK phosphorylation in vitro. In some
studies, the hippocampus has been identified as a target
site with high sensitivity to DA-induced toxicity [2,12,13].
A recent study demonstrated that abnormal ROS levels in
the hippocampus of DA-treated mice activate the stress-
activated protein kinase/c-Jun amino-terminal kinase
(SAPK/JNK) pathway in vivo [14], but no studies have
investigated ROS-mediated p38 MAPK signal transduction
pathways in the hippocampus after administration of DA.
The WD40 repeat present in some proteins is a small
structural motif of approximately 40 amino acids, typically
bracketed by glycine-histidine and tryptophan-aspartate
(GH-WD) [15]. Repeated WD40 motifs form a domain
called the WD domain that is involved in protein-protein
interactions. Proteins with WD40 repeats have important
roles in a variety of cellular functions such as cell growth,
proliferation, apoptosis, and intracellular signal transduc-
tion [15,16]. WD repeat-containing protein 35 (WDR35)
is a novel member of this protein family [17,18]. In a
mouse mutation screen for developmental phenotypes,
Mill et al. [18] identified a mutation in the WDR35 gene
as a cause of midgestation lethality associated with abnor-
malities characteristic of defects in the Hedgehog signaling
pathway. Recently, we cloned rat WDR35, also referred to
as naofen [19]. Very recently, we have found that bupiva-
caine, a local anesthetic, increases intracellular ROS levels
and activates p38 MAPK in mouse neuroblastoma Neu-
ro2a cells, resulting in apoptosis via an increase in the ex-
pression of WDR35 (under revision).
In the present study, we identified and quantified DA
in the brains of rats after intraperitoneal DA administra-
tion by using liquid chromatography/ion trap tandem
mass spectrometry (LC-MS/MS) analysis. We also per-
formed histological examinations of the hippocampus
after intraperitoneal DA administration in rats and investi-
gated the potential involvement of glutamate receptors,
ROS, p38 MAPK, and WDR35 in DA-induced toxicity.
Results
Identification and quantification of DA in the rat brain by
LC-MS/MS analysis
LC-MS/MS analysis was performed to confirm that
intraperitoneally administered DA reached the brain.The peak of the DA standard was detected at a retention
time of 8.3 min under the LC conditions used in this ex-
periment, and the full-scan mass spectrum showed the
exclusive presence of the [M +H]+ ion at m/z 312 (data
not shown). The MS/MS product ion spectra of DA,
obtained using the [M +H]+ ion at m/z 312 as precursor,
showed three fragment ions at m/z 248, m/z 266, and
m/z 294. As an example, an accumulated reconstructed
ion chromatogram (Figure 1A) of the three product ions
(m/z 312→ 248, 266, 294) and the MS/MS spectrum
(Figure 1B) for a 10 ng/ml standard DA solution are
shown. Representative LC-MS/MS analysis of a brain
sample from a rat obtained at 30 min after intraperito-
neal injection of 1 mg/kg DA shows the same retention
time (8.3 min) as that of the standard DA (Figure 1C)
and the presence of three diagnostic fragment ions
(Figure 1D) with the ion abundance ratios fully consist-
ent with those of the standard DA, thus confirming the
presence of DA in this brain sample.
Recovery tests were performed for quantification of
the concentrations of DA in brain samples. The recovery
of DA from brain samples spiked with 40 ng/g of DA
was examined by calculating the ratio of the amount of
analyte recovered after purification with the C18 cart-
ridge column to the amount originally added. Overall re-
coveries and coefficients of variation were found to be
satisfactory; these values were 84.4% and 11.0%, respect-
ively (n = 3). The mean concentration of DA in rat brain
samples obtained at 30 min after intraperitoneal admin-
istration of 1 mg/kg DA was 7.2 ± 0.75 ng/g (n = 3).
Histological examination of the CA1 region of rat
hippocampus following DA administration
Since LC-MS/MS analysis confirmed the distribution of
intraperitoneally administered DA (1 mg/kg) to the
brain, we carried out histological examinations of the
CA1 region of the rat hippocampus at 24 hours after
DA administration. Hematoxylin-Eosin staining showed
no neurodegenerative changes such as neuronal shrink-
age and cell dropout in the CA1 region after vehicle (sa-
line) administration (Figure 2A). In contrast, neuronal
shrinkage (arrow) and cell dropout (*) were observed
after DA administration (Figure 2B). As Giordano et al.
[7] reported that DA induces apoptosis in primary cul-
tures of mouse neurons, we used TUNEL staining to
examine whether intraperitoneal DA at 1 mg/kg induces
apoptosis in the CA1 region of the rat hippocampus.
TUNEL-positive neurons were not observed after vehicle
administration (Figure 2C). In contrast, at 24 hours after
DA administration, a few TUNEL-positive neurons were
observed (Figure 2D). Furthermore, at 5 days after DA
administration, many TUNEL-positive neurons were
observed (Figure 2E). Administration of 1 mg/kg DA sig-
nificantly increased the percentage of TUNEL positive
A B
C D
Figure 1 LC-MS/MS analysis of domoic acid. Intraperitoneally administered DA (1 mg/kg) was identified and quantified in the rat brain by LC-MS/MS
analysis. (A) Accumulated reconstructed ion chromatograms of the three product ions (m/z 312→ 248, 266, 294) having a retention time of 8.3 min and
(B) MS/MS spectrum for a 10 ng/ml standard solution of DA. (C) A brain sample from a rat taken at 30 min after intraperitoneal DA administration
(1 mg/kg) showing the same retention time as that of the standard DA and (D) the presence of three diagnostic fragment ions.
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1.7%, P < 0.001) compared with that of vehicle (1.7 ±
1.1%). Expression of WDR35 mRNA in the CA1 region
was not detected by in situ hybridization after adminis-
tration of vehicle (Figure 2F), whereas it was observed in
the soma of neurons after administration of DA
(Figure 2G). Furthermore, immunohistochemical stain-
ing for WDR35 showed weak expression of WDR35 in
the soma and axons of neurons (enclosed by the dotted
lines) after administration of vehicle (Figure 2H) and
strong expression of WDR35 in the soma and axons of
neurons (enclosed by the dotted lines) after administra-
tion of DA (Figure 2I). These results indicated that DAinduces the expression of WDR35 mRNA and protein in
neurons in the CA1 region of the hippocampus.
Quantitative examination of WDR35 expression in rat
hippocampus following DA administration
Subsequently, real-time RT-PCR and western blotting
analyses were performed to quantitatively examine the
increase in WDR35 expression in the hippocampus fol-
lowing intraperitoneal DA administration. As shown in
Figure 3A, administration of 1 mg/kg DA significantly
increased WDR35 mRNA expression to a level 2.1-fold
higher than the level observed after administration of ve-





Figure 2 (See legend on next page.)
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Figure 2 Histological examination of the CA1 region of rat hippocampus following DA administration. Rats were treated intraperitoneally
with either the control (vehicle) or DA (1 mg/kg). Tissues were collected at 24 hours (A-D, F-I) and 5 days (E) after treatment and prepared for
histology. Images are shown at × 50 (A, B) and × 100 (C-I) magnification. To clarify cell type-specific staining and subcellular staining, insets show
the same samples (indicated by arrowheads) at × 400 magnification. (A, B) Hematoxylin-Eosin staining (A) 24 hours after vehicle administration
and (B) 24 hours after DA administration. Arrow indicates neuronal shrinkage; asterisk indicates cell dropout. (C-E) TUNEL staining (C) 24 hours
after vehicle administration, (D) 24 hours after DA administration, and (E) 5 days after DA administration. Arrow indicates TUNEL-positive neuron.
(F, G) In situ hybridization (F) 24 hours after vehicle administration and (G) 24 hours after DA administration. Arrow indicates positive staining for
WDR35 mRNA. (H, I) Immunohistochemical staining for WDR35 (H) 24 hours after vehicle administration and (I) 24 hours after DA administration.
Positive staining neurons are enclosed by dotted lines.
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pression of WDR35 protein compared with administration
of vehicle. As the maximal effect was reached at 1 mg/kg
DA, a dose of 1 mg/kg of DA was used for the following
experiments.
As shown in Figure 3C, DA administration significantly
increased the expression of WDR35 mRNA at 24 hours,
when the level was 2.5-fold increased above the level at
hour 0. Furthermore, as shown in Figure 3D, DA adminis-
tration significantly increased the expression of WDR35
protein from 12 to 48 hours, with the maximal effect com-
pared with hour 0 reached at 24 hours. These results
showed that DA dose-dependently and time-dependently
increases WDR35 expression in the rat hippocampus.
Examination of the relationships between AMPA/KA
receptors, ROS and WDR35
Intraperitoneal injections of the selective glutamate recep-
tor antagonists NBQX (AMPA/KA receptor antagonist, 3
mg/kg) and MK-801 (NMDA receptor antagonist, 3 mg/kg)
were used to determine the types of glutamate receptors
involved in the upregulation of WDR35 expression in the
rat hippocampus at 24 hours after intraperitoneal DA ad-
ministration (1 mg/kg). Analysis of immunoblots showed
that NBQX significantly attenuated the DA-induced in-
crease in WDR35 protein expression (Figure 4A). In con-
trast, MK-801 did not alter the DA-induced increase in
WDR35 protein expression (Figure 4B). The antagonists
alone had no effect on WDR35 protein expression.
Several reports have shown that DA induces ROS
generation in vitro via activation of the AMPA/KA recep-
tor [6-8]. Therefore, we examined whether ROS might play
a role in the DA-induced increase in WDR35 protein
expression in the rat hippocampus by using the radical
scavenger edaravone (10 mg/kg, i.p.) that has been shown
to exert neuroprotective effects in animal models of several
brain disorders [20]. Analysis of immunoblots showed that
pretreatment with edaravone significantly attenuated the
DA-induced upregulation of WDR35 (Figure 4C).
Examination of the relationships between AMPA/KA
receptors, ROS and p38 MAPK
As Harper et al. [10] reported that ROS activates the
p38 MAPK pathway, we then investigated whetherintraperitoneal DA administration increases p38 MAPK
phosphorylation in the rat hippocampus. Treatment with
DA significantly increased p38 MAPK phosphorylation
in immunoblots of hippocampal tissue samples
(Figure 5A, 5B). We also examined the effect of NBQX
and edaravone on the DA-induced increase in p38
MAPK phosphorylation in the rat hippocampus. NBQX
and edaravone significantly attenuated DA-induced p38
MAPK phosphorylation in immunoblots of hippocampal
tissue samples (Figure 5A, 5B). No significant change in
the expression of p38 MAPK protein was observed.
These results suggested that activation of the AMPA/KA
receptor resulting in ROS generation followed by p38
MAPK phosphorylation might be involved in the DA-
induced upregulation of WDR35.
Discussion
LC-MS/MS has emerged as a powerful technique for the
identification and quantification of natural products, such
as toxins, in complicated matrices. In the present study,
we applied this technique to the analysis of DA in the rat
brain following an intraperitoneal dose of 1 mg/kg DA
and confirmed the presence of DA (Figure 1) at a mean
concentration of 7.2 ng/g tissue. A recent study using LC-
MS/MS reported that the concentration of DA in fetal rat
brains following an intravenous dose of 1 mg/kg DA in
pregnant rats was stable at a mean of 8.12 ng/g tissue [21].
Although the experimental conditions differed greatly be-
tween this study and ours, the concentration of DA
achieved in the brains of rats appeared to be comparable.
In the present study, neuronal shrinkage and cell
dropout were observed in the CA1 region of the rat
hippocampus at 24 hours after DA administration
(Figure 2B). Similar neurodegenerative changes were also
observed in rat brain in previous reports, although the
doses of DA, route of administration of DA, and time
course of measured effects were different in these studies:
2 mg/kg i.p. at 6–24 hours [22], 1.32 mg/kg i.p. at 8 days
[23], and 0.75 mg/kg i.v. at 5–21 days [24]. As reported
previously [8,24], TUNEL-positive cells were observed
following DA administration (Figure 2D, 2E). These obser-
vations suggest that in the present study, intraperitoneally
administered DA induced neurodegenerative changes
including apoptosis in the hippocampus.
Figure 3 Quantitative examination of WDR35 expression in rat hippocampus following DA administration. (A, B) DA was administered to
rats intraperitoneally at various doses. (A) WDR35 mRNA expression in hippocampal RNA preparations at 24 hours after DA administration was
analyzed by qRT-PCR and expressed relative to the expression of GAPDH mRNA. (B) WDR35 protein expression in hippocampal homogenates at
24 hours after DA administration was analyzed by western blotting. (C, D) DA (1 mg/kg) was administered to rats intraperitoneally and WDR35
mRNA expression (C) and WDR35 protein expression (D) were determined in hippocampal samples collected at the times indicated after DA
administration using the same methods as were used in (A) and (B). *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 4).
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expression may mediate apoptosis in several animal
models [25,26]. As expected, expression of WDR35 was
observed in neurons in the CA1 region of the rat hippo-
campus following DA administration (Figure 2G, 2I).Quantitative examination of WDR35 expression showed
that WDR35 is upregulated in the rat hippocampus
following DA administration. The increases in WDR35
mRNA and protein expression in the hippocampus were
both dose-dependent (Figure 3A, 3B) and time-dependent
AB
C
Figure 4 Examination of the relationships between AMPA/KA
receptors, ROS and WDR35. Rats were administered glutamate
receptor antagonists (3 mg/kg, i.p.) or edaravone (10 mg/kg, i.p.) at 1 hour
before intraperitoneal administration of DA. WDR35 protein expression at
24 hours after DA administration in hippocampal samples from rats
pretreated with (A) NBQX (AMPA/KA receptor antagonist), (B) MK-801
(NMDA receptor antagonist), or (C) edaravone (Ed, radical scavenger) was
analyzed by western blotting. *P< 0.05, **P< 0.01 and ***P< 0.001 (n = 4).
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of WDR35 may participate in the DA-induced neurode-
generative changes that were observed.
In studies in vitro, the toxicity of DA is mediated
mainly via activation of the AMPA/KA receptor [3-5],
whereas neurotoxicity is mediated secondarily via DA
activation of the NMDA receptor/Ca2+ pathway [27,28].
We examined the role of glutamate receptors in the
DA-induced increase in WDR35 expression by using
pharmacological blocking agents. We demonstrated that
an AMPA/KA receptor antagonist (NBQX) significantly
attenuated the DA-induced increase in WDR35 protein
expression in vivo (Figure 4A), but an NMDA receptor
antagonist (MK-801) did not (Figure 4B). These results
suggest that the AMPA/KA receptor could play a role in
DA-induced increases in WDR35 expression in vivo.
The induction of neuronal cell death by DA is
mediated by increased ROS production [6-8]. In
addition, kainic acid has been reported to stimulate ROS
generation [6]. These observations led us to investigate
the relationship between ROS and WDR35 expression
by using a radical scavenger, edaravone. We demon-
strated that edaravone significantly attenuated DA-
induced WDR35 expression (Figure 4C), suggesting that
DA-induced ROS production may increase the expres-
sion of WDR35 in vivo. In some studies, ROS have been
shown to activate p38 MAPK, eventually causing apop-
tosis [10]. In the present study, we demonstrated that
DA significantly increased p38 MAPK phosphorylation
in vivo, and this effect was significantly attenuated by
NBQX and edaravone (Figure 5A, 5B). Very recently, we
found that the local anesthetic bupivacaine increases
intracellular ROS levels and activates p38 MAPK, result-
ing in apoptosis via an increase in WDR35 expression in
mouse neuroblastoma Neuro2a cells (under revision).
Taking these observations into account, we speculate
that in the present study, the increase in ROS produc-
tion and activation of p38 MAPK by DA resulted in
increased expression of WDR35 in the rat hippocampus.
Although several studies demonstrated that DA
induces excitotoxic neuronal damage via activation of
glutamate receptors [8,24], the mechanistic cascades
have not been investigated in vivo. In the present study,
we provided the first evidence of the sequence of
mechanisms for DA-induced toxicity by histological and
biochemical examinations in vivo, in which DA activated
the AMPA/KA receptor, and induced ROS production
and p38 MAPK phosphorylation, resulting in an increase
in the expression of WDR35. Our findings will be useful
for future studies such as possible involvement of tran-
scription factors of activating protein-1 (AP-1) and nu-
clear factor-kappa B (NF-κB) families in DA-induced
toxicity, and detailed sequence of events including the
role of WDR35.
A B
Figure 5 Examination of the relationships between AMPA/KA receptors, ROS and p38 MAPK. Rats were administered (A) NBQX (3 mg/kg,
i.p.) or (B) edaravone (10 mg/kg, i.p.) at 1 hour before intraperitoneal administration of DA. Expression of p38 and phospho-p38 MAPK in rat
hippocampus at 24 hours after intraperitoneal DA administration was analyzed by western blotting. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 3-7).
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In conclusion, our results indicated that DA activated
the AMPA/KA receptor, and induced ROS production
and p38 MAPK phosphorylation, resulting in an increase
in the expression of WDR35.
Methods
Reagents
Domoic acid (Sigma, St. Louis, MO, USA) was
dissolved in saline solution (0.9% NaCl) at 1 mg/ml.
The glutamate receptor antagonists, 2,3-dioxo-6-
nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX, Sigma,
St. Louis, MO, USA) and dizocilpine maleate (MK-801,
Tocris Bioscience, Ellisville, MO, USA) were dissolved
in saline solution at 3 mg/ml. Edaravone (Tocris Bio-
science, Ellisville, MO, USA) was dissolved in dimethyl
sulfoxide at 10 mg/ml.
Animals and treatments
Eight-week-old male Sprague–Dawley rats weighing ap-
proximately 300 g were purchased from SLC (Shizuoka,
Japan) and habituated to the laboratory for 1 week
before the experiments began. All procedures were
approved by the Animal Care Committee of Aichi Med-
ical University. All rats were kept in a climate-controlled
room under 12/12-hour light–dark cycles with free ac-
cess to food and tap water throughout the studies.
For the mass spectrometric analysis, rats were admi-
nistered DA intraperitoneally at a dose of 1 mg/kg.
Thirty minutes later, the rats were deeply anesthetized
with pentobarbital sodium and were then perfused
transcardially with cold phosphate-buffered saline (PBS).The brains were then removed and weighed. For histo-
logical examinations, rats were administered DA (1 mg/kg)
or vehicle intraperitoneally. At 24 hours or 5 days
after DA or vehicle administration, rats were deeply
anesthetized with pentobarbital sodium and perfused
transcardially with cold PBS followed by cold 4% paraf-
ormaldehyde in PBS, pH 7.2. The brains were removed
and postfixed with 4% paraformaldehyde at 4°C for 24 h,
then were dehydrated and embedded in paraffin. The
paraffin blocks were stored at 4°C. Sections were cut at a
thickness of 4 μm and processed for Hematoxylin-Eosin
staining, in situ hybridization, immunohistochemistry,
and TUNEL staining. For the qRT-PCR and western blot
experiments, DA or vehicle administered rats were sacri-
ficed by decapitation. The brains were rapidly excised,
and hippocampi were rapidly dissected on an ice-cold
dissection board. For dose–response studies, rats were
administered DA intraperitoneally at doses of 0.3, 1, and
3 mg/kg and were sacrificed 24 hours later. For time-
course studies, rats were sacrificed at 0, 6, 12, 24, and 48
hours after intraperitoneal administration of 1 mg/kg
DA. Seizures [29] were observed in 3 mg/kg group. For
pretreatment studies, NBQX, MK-801, and edaravone
were administered to rats intraperitoneally at one hour
before DA administration, and the rats were sacrificed at
24 hours after DA administration. Control rats received
an equivalent volume of vehicle.
Preparation of extracts from rat brains for mass
spectrometric analysis
Isolated rat brains were minced in 50% aqueous metha-
nol (8 ml), homogenized, and centrifuged at 10,000 g for
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column of Sep-PakW Plus C18 (Waters Co., Milford,
MA, USA), and filtered with AmiconW Ultra 0.5 ml 10 K
centrifugal filter devices (Millipore Co., Billerica, MA,
USA). The filtrate was subjected to LC-MS/MS analysis.
LC-MS/MS
The LC separation was performed using an ACCELA
HPLC system (Thermo Fisher Scientific, Waltham, MA,
USA). Separation was accomplished with a TSK-GEL
ODS-80Ts column (150 × 2.0 mm, Tosoh, Tokyo, Japan)
at 30°C. Water containing 0.1% formic acid was used as
eluent A, and acetonitrile containing 0.1% formic acid
was used as eluent B. The LC elution gradient employed
was: 0 to 5 min 100% A, 5 to 10 min eluent A decreased
linearly to 50%, and 10 to 12 min 100% B. The eluent
shifted back to 100% A and was held for 3 min to equili-
brate the column for the next sample. The flow rate was
0.5 ml/min. The MS analysis was accomplished using a
LTQ Velos spectrometer (Thermo Fisher Scientific, San
Jose, CA, USA) equipped with a heated electrospray
ionization (HESI) source. Positive ion HESI was chosen
for the detection of DA. The source voltage was set at 3
kV, the capillary temperature was set at 350°C, and the
tube lens offset was set at 15 V. The sheath gas flow rate
was 35 (arbitrary units) and the auxiliary gas flow rate
was 10 (arbitrary units). Full scan experiments were per-
formed in the range m/z 50–1000. The total number of
microscans was set at 1 and the maximum injection time
at 10 ms. Subsequent MS/MS experiments were per-
formed in the range m/z 85–400. The maximum injec-
tion time was set at 100 ms. Reproducible calibration
curves for DA were obtained with correlation coeffi-
cients greater than 0.999 (known concentration versus
analyte), and the curves were linear over the range of
0.2-10 ng/ml.
In situ hybridization
The sequence of the WDR35 probe was 50AAGCACA
AACTGAGGGTGATTTTCATCAGC-30. Hybridization
was performed at 105°C for 5 minutes and 50°C for 3
hours, with the probe diluted at 1:1000. The
hybridization signal was amplified with the TSA Biotin
System (PerkinElmer, Waltham, MA, USA) and visua-
lized with DAB (Falma, Tokyo, Japan). The sections
were counterstained with hematoxylin as described previ-
ously [25].
Immunohistochemical staining for WDR35
Rat brain sections were treated with 3% H2O2 in metha-
nol for 30 min to inactive endogenous peroxidase,
blocked at room temperature for 60 min with 4% goat
serum albumin in PBS, and rinsed in 0.01 M PBS with
0.1% Tween20W (PBS-T). Sections were then incubatedat room temperature overnight with anti-WDR35 anti-
body (1:1000, Abcam, Cambridge, UK) in PBS-T. Immu-
nohistochemical staining was done according to the
manufacturer’s protocol using a Vectastain ABC Elite kit
(Vector Laboratories Inc., Burlingame, CA, USA) with
the 3,30-diaminobenzidine (DAB) reaction. Sections were
counterstained with hematoxylin. Sections with no pri-
mary antibody were included as negative controls to
verify the secondary antibody specificity.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) assay
TUNEL was performed using the ApopTagW Plus In Situ
Apoptosis Detection Kit (Chemicon International,
Temecula, CA, USA) according to the manufacturer’s
instructions and visualized with the TSA Biotin System
and DAB. The sections were counterstained with 0.5%
methyl green (Wako Pure Chemicals, Osaka, Japan).
Apoptotic and nonapoptotic cells were counted in three
randomly chosen microscopic fields, and results are
expressed as percentage of apoptotic cells ± S.E.
Quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR)
Total RNA (1 μg) was extracted from rat hippocampus
homogenate with TRIzolW reagent (Invitrogen, Carlsbad,
CA, USA) and reverse transcribed with a ReverTra Ace
qPCR RT kit (Toyobo, Osaka, Japan). Quantitative
RT-PCR was performed as described previously [26]
with the ABI StepOne Plus real-time PCR system and a
Taqman Gene Expression Assay (Applied Biosystems,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. WDR35 mRNA levels were quantified relative to
GAPDH mRNA levels, the internal control. The results
are presented according to the ΔΔCT method as ratios
of the target to the internal control as described previ-
ously [26].
Western blot analysis
Rat hippocampi were homogenized in lysis buffer [62.5
mM Tris–HCl (pH6.8), 2.5% SDS, 10% glycerol] containing
a protease inhibitor cocktail (Roche Applied Sciences,
Mannheim, Germany) and heated in boiling water
for 5 min. After centrifugation, the supernatants were
collected, and the protein concentration of samples was
determined by the DC protein assay (Bio-Rad Laborator-
ies, Hercules, CA, USA). Samples (30 μg protein) were
mixed with 2-mercaptoethanol and Bromo Phenol Blue
buffer, separated by SDS-PAGE, and transferred to PVDF
membranes (Millipore Corporation, Billerica, MA, USA).
The blots were incubated with rabbit antibodies against
WDR35 (132kDa, 1:1000; Abcam, Cambridge, UK), p38
MAPK (43 kDa, 1:1000; Cell Signaling Technology,
Danvers, MA, USA), phospho-p38 MAPK (43 kDa,
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http://www.biomedcentral.com/1471-2202/14/41:1000; Cell Signaling Technology) or GAPDH (37 kDa,
1:20,000; Cell Signaling Technology) followed by
peroxidase-conjugated anti-rabbit IgG (1:5000; Zymed La-
boratories, San Francisco, CA, USA). The apparent mo-
lecular weight of each protein was determined by BlueStar
Prestained Protein Marker (Nippon Genetics Europe
GmbH, Dueren, Germany). Detection was performed with
the ECL Prime Western Blotting Reagent (GE Healthcare,
Buckinghamshire, UK). Protein levels were quantified by
densitometric scanning and expressed as the ratio to
GAPDH, as described previously [30].
Statistical analysis
All results were expressed as mean ± standard error of the
mean (SEM). Data were analyzed for statistical signifi-
cance with one-way analysis of variance (ANOVA), fol-
lowed by post hoc analysis with the Bonferroni method.
Differences were considered significant at P < 0.05.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KT carried out the histological and biochemical studies, performed the
statistical analysis, and drafted the manuscript. FK carried out the LC-MS/MS
study, performed the statistical analysis, participated in the study design,
drafted and critically appraised the manuscript. TO participated in the
histological studies and helped to draft the manuscript. GGF and LH
participated in the biochemical experiments and contributed to data
acquisition and analysis. NI was involved in the conceptualization of the
study. SO conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported in part by a Strategic Research Foundation Grant-aided
Project for Private Universities grant (S1101027) from the Ministry of Education,
Culture, Sports, Science, and Technology, Japan.
Received: 26 July 2012 Accepted: 3 January 2013
Published: 7 January 2013
References
1. Sari P, Kerr DS: Domoic acid-induced hippocampal CA1 hyperexcitability
independent of region CA3 activity. Epilepsy Res 2001, 47(1–2):65–76.
2. Perez-Gomez A, Tasker RA: Enhanced neurogenesis in organotypic
cultures of rat hippocampus after transient subfield-selective excitotoxic
insult induced by domoic acid. Neuroscience 2012, 208:97–108.
3. Novelli A, Kispert J, Fernandez-Sanchez MT, Torreblanca A, Zitko V: Domoic acid-
containing toxic mussels produce neurotoxicity in neuronal cultures through
a synergism between excitatory amino acids. Brain Res 1992, 577(1):41–48.
4. Hogberg HT, Bal-Price AK: Domoic acid-induced neurotoxicity is mainly
mediated by the AMPA/KA receptor: comparison between immature
and mature primary cultures of neurons and glial cells from rat
cerebellum. J Toxicol 2011, 2011:543512.
5. Giordano G, White CC, Mohar I, Kavanagh TJ, Costa LG: Glutathione levels
modulate domoic acid induced apoptosis in mouse cerebellar granule
cells. Toxicol Sci 2007, 100(2):433–444.
6. Bondy SC, Lee DK: Oxidative stress induced by glutamate receptor
agonists. Brain Res 1993, 610(2):229–233.
7. Giordano G, White CC, McConnachie LA, Fernandez C, Kavanagh TJ, Costa LG:
Neurotoxicity of domoic acid in cerebellar granule neurons in a genetic
model of glutathione deficiency. Mol Pharmacol 2006, 70(6):2116–2126.
8. Xu R, Tao Y, Wu C, Yi J, Yang Y, Yang R, Hong D: Domoic acid induced
spinal cord lesions in adult mice: evidence for the possible molecularpathways of excitatory amino acids in spinal cord lesions. Neurotoxicology
2008, 29(4):700–707.
9. Cuadrado A, Nebreda AR: Mechanisms and functions of p38 MAPK
signalling. Biochem J 2010, 429(3):403–417.
10. Harper SJ, LoGrasso P: Signalling for survival and death in neurones: the role
of stress-activated kinases, JNK and p38. Cell Signal 2001,
13(5):299–310.
11. Giordano G, Klintworth HM, Kavanagh TJ, Costa LG: Apoptosis induced by
domoic acid in mouse cerebellar granule neurons involves activation of
p38 and JNK MAP kinases. Neurochem Int 2008, 52(6):1100–1105.
12. Strain SM, Tasker RA: Hippocampal damage produced by systemic
injections of domoic acid in mice. Neuroscience 1991,
44(2):343–352.
13. Gill DA, Ramsay SL, Tasker RA: Selective reductions in subpopulations of
GABAergic neurons in a developmental rat model of epilepsy. Brain Res
2010, 1331:114–123.
14. Wu DM, Lu J, Zheng YL, Zhang YQ, Hu B, Cheng W, Zhang ZF, Li MQ: Small
interfering RNA-mediated knockdown of protein kinase C zeta
attenuates domoic acid-induced cognitive deficits in mice. Toxicol Sci
2012, 128(1):209–222.
15. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF: The ancient regulatory-
protein family of WD-repeat proteins. Nature 1994, 371(6495):297–300.
16. Smith TF, Gaitatzes C, Saxena K, Neer EJ: The WD repeat: a common
architecture for diverse functions. Trends Biochem Sci 1999, 24(5):181–185.
17. Gilissen C, Arts HH, Hoischen A, Spruijt L, Mans DA, Arts P, van Lier B,
Steehouwer M, van Reeuwijk J, Kant SG, Roepman R, Knoers NV, Veltman JA,
Brunner HG: Exome sequencing identifies WDR35 variants involved in
Sensenbrenner syndrome. Am J Hum Genet 2010, 87(3):418–423.
18. Mill P, Lockhart PJ, Fitzpatrick E, Mountford HS, Hall EA, Reijns MA, Keighren
M, Bahlo M, Bromhead CJ, Budd P, Aftimos S, Delatycki MB, Savarirayan R,
Jackson IJ, Amor DJ: Human and mouse mutations in WDR35 cause
short-rib polydactyly syndromes due to abnormal ciliogenesis. Am J Hum
Genet 2011, 88(4):508–515.
19. Feng GG, Li C, Huang L, Tsunekawa K, Sato Y, Fujiwara Y, Komatsu T, Honda
T, Fan JH, Goto H, Koide T, Hasegawa T, Ishikawa N: Naofen, a novel WD40-
repeat protein, mediates spontaneous and tumor necrosis factor-
induced apoptosis. Biochem Biophys Res Commun 2010,
394(1):153–157.
20. Ohta M, Higashi Y, Yawata T, Kitahara M, Nobumoto A, Ishida R, Tsuda M,
Fujimoto Y, Shimizu K: Attenuation of axonal injury and oxidative stress
by edaravone protects against cognitive impairments after traumatic
brain injury. Brain Res 2012, Epub ahead of print.
21. Fuquay JM, Muha N, Wang Z, Ramsdell JS: Toxicokinetics of domoic acid
in the fetal rat. Toxicology 2012, 294(1):36–41.
22. Tryphonas L, Truelove J, Nera E, Iverson F: Acute neurotoxicity of domoic
acid in the rat. Toxicol Pathol 1990, 18(1 Pt 1):1–9.
23. Sobotka TJ, Brown R, Quander DY, Jackson R, Smith M, Long SA, Barton CN,
Rountree RL, Hall S, Eilers P, Johannessen JN, Scallet AC: Domoic acid:
neurobehavioral and neurohistological effects of low-dose exposure in
adult rats. Neurotoxicol Teratol 1996, 18(6):659–670.
24. Ananth C, Thameem Dheen S, Gopalakrishnakone P, Kaur C: Domoic acid-
induced neuronal damage in the rat hippocampus: changes in apoptosis
related genes (bcl-2, bax, caspase-3) and microglial response. J Neurosci
Res 2001, 66(2):177–190.
25. Sato Y, Feng GG, Huang L, Fan JH, Li C, An J, Tsunekawa K, Kurokawa S,
Fujiwara Y, Komatsu T, Kondo F, Ishikawa N: Enhanced expression of naofen
in kidney of streptozotocin-induced diabetic rats: possible correlation to
apoptosis of tubular epithelial cells. Clin Exp Nephrol 2010,
14(3):205–212.
26. Fan JH, Feng GG, Huang L, Tsunekawa K, Honda T, Katano Y, Hirooka Y,
Goto H, Kandatsu N, Ando K, Fujiwara Y, Koide T, Okada S, Ishikawa N: Role
of naofen in apoptosis of hepatocytes induced by lipopolysaccharide
through mitochondrial signaling in rats. Hepatol Res 2012,
42(7):696–705.
27. Berman FW, Murray TF: Domoic acid neurotoxicity in cultured cerebellar
granule neurons is mediated predominantly by NMDA receptors that are
activated as a consequence of excitatory amino acid release.
J Neurochem 1997, 69(2):693–703.
28. Berman FW, LePage KT, Murray TF: Domoic acid neurotoxicity in cultured
cerebellar granule neurons is controlled preferentially by the NMDA
receptor Ca(2+) influx pathway. Brain Res 2002, 924(1):20–29.
Tsunekawa et al. BMC Neuroscience 2013, 14:4 Page 11 of 11
http://www.biomedcentral.com/1471-2202/14/429. Fuquay JM, Muha N, Pennington PL, Ramsdell JS: Domoic acid induced
status epilepticus promotes aggressive behavior in rats. Physiol Behav
2012, 105(2):315–320.
30. An J, Feng GG, Huang L, Kurokawa T, Nonami T, Koide T, Kondo F, Komatsu T,
Tsunekawa K, Fujiwara Y, Goto H, Nishikawa H, Miki T, Sugiyama S, Ishikawa N:
Effects of 1-O-hexyl-2,3,5-trimethylhydroquinone on carbon tetrachloride-
induced hepatic cirrhosis in rats. Hepatol Res 2010, 40(6):613–621.
doi:10.1186/1471-2202-14-4
Cite this article as: Tsunekawa et al.: Enhanced expression of WD repeat-
containing protein 35 (WDR35) stimulated by domoic acid in rat
hippocampus: involvement of reactive oxygen species generation and p38
mitogen-activated protein kinase activation. BMC Neuroscience 2013 14:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
